Mutagen sensitivity exhibits a dose-response relationship in case-control studies

Area of Science:

• Genetics
• Oncology
• Biochemistry

Background:

• Assessing cancer susceptibility is crucial for early detection and prevention.
• Induced chromatid breaks in lymphocytes serve as a potential biomarker for cancer risk.
• Previous studies suggest a link between genetic instability and cancer development.

Purpose of the Study:

• To evaluate the consistency of induced chromatid breaks as a marker of cancer susceptibility across different cancer types.
• To investigate the correlation between elevated chromatid breaks and the risk of developing lung cancer and melanoma.
• To explore the dose-response relationship between mutagen exposure and chromatid breaks in relation to cancer risk.

Main Methods:

• Conducted two case-control studies focusing on lung cancer and melanoma.
• Quantitated induced chromatid breaks in lymphocyte cultures exposed to specific chemical mutagens (bleomycin for lung cancer, 4-nitroquinoline-oxide for melanoma).
• Analyzed data by comparing mean breaks/cell between cases and controls, and by dichotomizing data at the 75th percentile of control breaks, and by categorizing data into quartiles.

Main Results:

• Both studies demonstrated significantly higher mean numbers of induced chromatid breaks/cell in cancer cases compared to controls.
• Dichotomizing data revealed significantly elevated adjusted odds ratios (3.7 for lung cancer, 5.0 for melanoma) in cases.
• Dose-response relationships were observed, with the highest risk estimates in the top quartile of induced breaks.

Conclusions:

• Quantitation of induced chromatid breaks in lymphocytes is a consistent and reliable marker for cancer susceptibility.
• Elevated levels of induced chromatid breaks are significantly associated with increased risk for lung cancer and melanoma.
• This assay holds potential for broader application in assessing cancer risk across various cancer sites and with different mutagens.